News
Winners to be Revealed September 10 at Fierce Pharma Marketing Awards Gala in Philadelphia, During the Fierce Pharma Week ...
ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks.
Acknowledging the limits of disease-modifying drugs like Leqembi and Kisunla, companies like Bristol Myers Squibb, Acadia, ...
Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $29.06, along ...
As the U.S. stock market continues to flirt with record highs, driven by strong earnings reports and investor optimism, the tech-heavy Nasdaq Composite stands out as a key player in this bullish trend ...
Detailed price information for Acadia Pharmaceutica (ACAD-Q) from The Globe and Mail including charting and trades.
More than thirty years since its 1993 founding, Catherine Owen Adams and Elizabeth Thompson—the R&D combo that has led Acadia ...
StockStory.org on MSN17d
Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market ...
The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chro ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company specializing in central nervous system (CNS) disorders, is navigating a critical phase of growth and expansion. With a robust ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on July 2, 2025, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results